Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate ProgressGlobeNewsWire • 02/26/25
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025GlobeNewsWire • 02/19/25
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?Zacks Investment Research • 02/10/25
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewsWire • 01/29/25
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 01/16/25
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/05/24
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/04/24
Revolution Medicines Announces Commencement of Public Offering of Common StockGlobeNewsWire • 12/02/24
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor PortfolioGlobeNewsWire • 12/02/24
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024GlobeNewsWire • 11/27/24
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate ProgressGlobeNewsWire • 11/06/24
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024GlobeNewsWire • 10/30/24
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 10/25/24
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 10/23/24
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 10/21/24
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor WebcastGlobeNewsWire • 10/07/24
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate ProgressGlobeNewsWire • 08/07/24